Headquartered in Avenue De La Grande Armee, Paris Fiscal year ends December NASDAQ: SNY sanofi.com
Sanofi is a global biopharmaceutical company organized around a single Biopharma segment that develops, manufactures, and markets prescription medicines and vaccines. Its portfolio spans immunology (anchored by the blockbuster Dupixent franchise for atopic dermatitis, asthma, COPD, and multiple other inflammatory conditions), rare diseases (including treatments for Gaucher, Pompe, and Fabry diseases, haemophilia, and systemic mastocytosis), oncology (Sarclisa for multiple myeloma), and general medicines (insulins Lantus and Toujeo, cardiovascular drug Plavix, and anticoagulant Lovenox). The vaccines business covers influenza (Fluzone HD/Efluelda), RSV prevention (Beyfortus), polio/pertussis/hib combinations, meningitis, and COVID-19 (Nuvaxovid). Sanofi completed the acquisition of Dynavax in February 2026, adding the adult hepatitis B vaccine Heplisav-B and a shingles vaccine candidate. The company divested its consumer healthcare unit Opella to CD&R in 2025 but retains a 48.2% indirect equity stake. Sanofi collaborates extensively with Regeneron on Dupixent and Kevzara, and maintains a pipeline of 77 projects across immunology, rare diseases, vaccines, neurology, and oncology, with key late-stage assets including amlitelimab (atopic dermatitis), duvakitug (inflammatory bowel disease), lunsekimig (asthma/CRSwNP), frexalimab (multiple sclerosis, kidney transplant), and venglustat (Gaucher disease type 3). The company reports in euros and derives approximately 51% of sales in US dollars. Updated
Sanofi set a new 52-week low at $40.67, taking out Monday's floor by 0.17% and leaving the $106 billion drugmaker at its weakest level in a year. Each new bottom this week has come by a sliver, so the next support test is the one to watch.
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing. My tenure at these premier Wall Street firms exposed…
Investors have been running on a high for the last several months as all major U.S. indices have reached new record levels seemingly month after month. Sentiment on the stock market has…
It was nice while it lasted, and it may not be over, but the AI-driven stock market rally may run out of gas fast. While the Magnificent 7 has soared (the group…
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third…
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the country ages;…
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of…
Here are six European Dividend Aristocrats that are the most liquid and well-known for U.S. investors who are looking for income and a degree of diversification away from the American indexes.
For growth and income investors, adding top-quality dividend stocks based in Europe to domestic portfolios may be a solid way to go for the rest of the year. These five top European…
With a recession likely on the way, health care is the place to be in 2023 for long-term investors looking for growth and income. These seven industry leaders offer solid total return…
In what could be a long and brutal bear market in the United States, it may make sense for investors to look to Europe for some ideas now. These five top European…
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy…
Sanofi is a global biopharmaceutical company organized around a single Biopharma segment that develops, manufactures, and markets prescription medicines and vaccines.
24/7 Wall St.'s 12-month price target for SNY is $50.10, rated Buy. The Wall Street consensus target is $53.61. SNY price prediction →
